Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jounce Therapeutics Inc (JNCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 190,233
  • Shares Outstanding, K 32,630
  • Annual Sales, $ 71,640 K
  • Annual Income, $ -16,440 K
  • 36-Month Beta 5.33
  • Price/Sales 2.66
  • Price/Cash Flow N/A
  • Price/Book 1.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.34
  • Number of Estimates 6
  • High Estimate -0.27
  • Low Estimate -0.42
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -161.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.43 +2.76%
on 10/19/18
7.30 -23.56%
on 10/04/18
-1.11 (-16.59%)
since 09/19/18
3-Month
5.43 +2.76%
on 10/19/18
8.58 -34.97%
on 08/24/18
-2.20 (-28.28%)
since 07/19/18
52-Week
5.43 +2.76%
on 10/19/18
29.25 -80.92%
on 03/13/18
-9.02 (-61.78%)
since 10/19/17

Most Recent Stories

More News
New Research Coverage Highlights Himax Technologies, Corporacion America Airports S.A, Tecnoglass, Jounce Therapeutics, Hollysys Automation Technologies, and Obsidian Energy -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Himax Technologies, Inc....

CAAP : 8.16 (+0.37%)
OBE : 0.83 (+6.41%)
JNCE : 5.58 (-4.29%)
HOLI : 19.51 (-0.20%)
HIMX : 6.05 (-1.63%)
TGLS : 9.58 (-1.84%)
Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that its scientific...

JNCE : 5.58 (-4.29%)
Jounce Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Hugh Cole, chief...

JNCE : 5.58 (-4.29%)
Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 62.16% and 55.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?...

JNCE : 5.58 (-4.29%)
Jounce Therapeutics Reports Second Quarter 2018 Financial Results

- Initiated enrollment in dose escalation cohorts of Phase 1/2 ICONIC trial of JTX-2011, in combination with ipilimumab and in combination with pembrolizumab -

JNCE : 5.58 (-4.29%)
Jounce Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Jounce Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:00 AM Eastern Time....

JNCE : 5.58 (-4.29%)
Free Technical Research on Intrexon and Three More Biotech Equities

Stock Research Monitor: IONS, JNCE, and KERX

JNCE : 5.58 (-4.29%)
XON : 13.95 (-3.59%)
IONS : 45.19 (-2.50%)
Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting

ICONIC Target Enrollment Met Across Four Combination Cohorts

JNCE : 5.58 (-4.29%)
Jounce Therapeutics Reports First Quarter 2018 Financial Results

- Preliminary efficacy data from Phase 1/2 ICONIC trial to be presented as an oral presentation at the 2018 ASCO Annual Meeting -

JNCE : 5.58 (-4.29%)
Jounce Therapeutics to Present at Deutsche Bank 43rd Annual Health Care Conference

Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced...

JNCE : 5.58 (-4.29%)
DB : 10.92 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade JNCE with:

Business Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator,...

See More

Key Turning Points

2nd Resistance Point 6.26
1st Resistance Point 5.92
Last Price 5.58
1st Support Level 5.34
2nd Support Level 5.09

See More

52-Week High 29.25
Fibonacci 61.8% 20.15
Fibonacci 50% 17.34
Fibonacci 38.2% 14.53
Last Price 5.58
52-Week Low 5.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar